Cargando…
Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy
BACKGROUND: Prostate cancer is a one of the most common malignant diseases in men worldwide. Now it is a challenge to identify patients at higher risk for relapse and progression after surgery, and more novel prognostic biomarkers are needed. The aim of this study was to investigate the clinical sig...
Autores principales: | Lin, Ying-Li, Deng, Qiu-Kui, Wang, Yu-Hao, Fu, Xing-Li, Ma, Jian-Guo, Li, Wen-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689382/ https://www.ncbi.nlm.nih.gov/pubmed/26683656 http://dx.doi.org/10.12659/MSM.896763 |
Ejemplares similares
-
Aberrant Methylation of Protocadherin 17 and its Clinical Significance in Patients with Prostate Cancer after Radical Prostatectomy
por: Lin, Ying-Li, et al.
Publicado: (2014) -
Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma
por: Lin, Ying-Li, et al.
Publicado: (2017) -
Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients
por: Deng, Qiu-Kui, et al.
Publicado: (2016) -
Aberrant Methylation of PCDH10 Predicts Worse Biochemical Recurrence-Free Survival in Patients with Prostate Cancer After Radical Prostatectomy
por: Wang, Li, et al.
Publicado: (2014) -
Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer
por: Lin, Ying-Li, et al.
Publicado: (2017)